Equine mesenchymal stem cells inhibit T cell proliferation through different mechanisms depending on tissue source

Danielle D. Carrade Holt, Joshua Wood, Jennifer L. Granick, Naomi J. Walker, Kaitlin C. Clark, Dori L Borjesson

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Mesenchymal stem cells (MSCs) are used in both human clinical trials and veterinary medicine for the treatment of inflammatory and immune-mediated diseases. MSCs modulate inflammation by decreasing the cells and products of the inflammatory response. Stimulated equine MSCs from bone marrow (BM), adipose tissue (AT), cord blood (CB), and umbilical cord tissue (CT) inhibit lymphocyte proliferation and decrease inflammatory cytokine production. We hypothesized that equine MSCs inhibit T cell proliferation through secreted mediators and that MSCs from different tissue sources decrease T cell proliferation through different mechanisms. To test our hypotheses, we inhibited interleukin-6 (IL-6), nitric oxide (NO), and prostaglandin E2 (PGE2) to determine their impact on stimulated T cell proliferation. We also determined how equine MSCs modulate lymphocyte proliferation either via cell cycle arrest or apoptosis. Inhibition of IL-6 or NO did not reverse the immunomodulatory effect of MSCs on activated T cells. In contrast, inhibition of PGE2 restored T cell proliferation, restored the secretion of tumor necrosis factor-α and interferon-γ, and increased IL-10 levels. MSCs from solid-tissue-derived sources, AT and CT, inhibited T cell proliferation through induction of lymphocyte apoptosis while blood-derived MSCs, BM and CB, induced lymphocyte cell cycle arrest. Equine MSCs from different tissue sources modulated immune cell function by both overlapping and unique mechanisms. MSC tissue source may determine immunomodulatory properties of MSCs and may have very practical implications for MSC selection in the application of MSC therapy.

Original languageEnglish (US)
Pages (from-to)1258-1265
Number of pages8
JournalStem Cells and Development
Volume23
Issue number11
DOIs
StatePublished - Jun 1 2014

Fingerprint

Mesenchymal Stromal Cells
Horses
Cell Proliferation
T-Lymphocytes
Fetal Blood
Lymphocytes
Cell Cycle Checkpoints
Dinoprostone
Adipose Tissue
Interleukin-6
Nitric Oxide
Bone Marrow
Apoptosis
Veterinary Medicine
Clinical Medicine
Immune System Diseases
Cell- and Tissue-Based Therapy
Interleukin-10
Interferons
Tumor Necrosis Factor-alpha

ASJC Scopus subject areas

  • Cell Biology
  • Developmental Biology
  • Hematology
  • Medicine(all)

Cite this

Equine mesenchymal stem cells inhibit T cell proliferation through different mechanisms depending on tissue source. / Carrade Holt, Danielle D.; Wood, Joshua; Granick, Jennifer L.; Walker, Naomi J.; Clark, Kaitlin C.; Borjesson, Dori L.

In: Stem Cells and Development, Vol. 23, No. 11, 01.06.2014, p. 1258-1265.

Research output: Contribution to journalArticle

Carrade Holt, Danielle D. ; Wood, Joshua ; Granick, Jennifer L. ; Walker, Naomi J. ; Clark, Kaitlin C. ; Borjesson, Dori L. / Equine mesenchymal stem cells inhibit T cell proliferation through different mechanisms depending on tissue source. In: Stem Cells and Development. 2014 ; Vol. 23, No. 11. pp. 1258-1265.
@article{ae6f186b7be74427b84ce7586e6ef323,
title = "Equine mesenchymal stem cells inhibit T cell proliferation through different mechanisms depending on tissue source",
abstract = "Mesenchymal stem cells (MSCs) are used in both human clinical trials and veterinary medicine for the treatment of inflammatory and immune-mediated diseases. MSCs modulate inflammation by decreasing the cells and products of the inflammatory response. Stimulated equine MSCs from bone marrow (BM), adipose tissue (AT), cord blood (CB), and umbilical cord tissue (CT) inhibit lymphocyte proliferation and decrease inflammatory cytokine production. We hypothesized that equine MSCs inhibit T cell proliferation through secreted mediators and that MSCs from different tissue sources decrease T cell proliferation through different mechanisms. To test our hypotheses, we inhibited interleukin-6 (IL-6), nitric oxide (NO), and prostaglandin E2 (PGE2) to determine their impact on stimulated T cell proliferation. We also determined how equine MSCs modulate lymphocyte proliferation either via cell cycle arrest or apoptosis. Inhibition of IL-6 or NO did not reverse the immunomodulatory effect of MSCs on activated T cells. In contrast, inhibition of PGE2 restored T cell proliferation, restored the secretion of tumor necrosis factor-α and interferon-γ, and increased IL-10 levels. MSCs from solid-tissue-derived sources, AT and CT, inhibited T cell proliferation through induction of lymphocyte apoptosis while blood-derived MSCs, BM and CB, induced lymphocyte cell cycle arrest. Equine MSCs from different tissue sources modulated immune cell function by both overlapping and unique mechanisms. MSC tissue source may determine immunomodulatory properties of MSCs and may have very practical implications for MSC selection in the application of MSC therapy.",
author = "{Carrade Holt}, {Danielle D.} and Joshua Wood and Granick, {Jennifer L.} and Walker, {Naomi J.} and Clark, {Kaitlin C.} and Borjesson, {Dori L}",
year = "2014",
month = "6",
day = "1",
doi = "10.1089/scd.2013.0537",
language = "English (US)",
volume = "23",
pages = "1258--1265",
journal = "Stem Cells and Development",
issn = "1547-3287",
publisher = "Mary Ann Liebert Inc.",
number = "11",

}

TY - JOUR

T1 - Equine mesenchymal stem cells inhibit T cell proliferation through different mechanisms depending on tissue source

AU - Carrade Holt, Danielle D.

AU - Wood, Joshua

AU - Granick, Jennifer L.

AU - Walker, Naomi J.

AU - Clark, Kaitlin C.

AU - Borjesson, Dori L

PY - 2014/6/1

Y1 - 2014/6/1

N2 - Mesenchymal stem cells (MSCs) are used in both human clinical trials and veterinary medicine for the treatment of inflammatory and immune-mediated diseases. MSCs modulate inflammation by decreasing the cells and products of the inflammatory response. Stimulated equine MSCs from bone marrow (BM), adipose tissue (AT), cord blood (CB), and umbilical cord tissue (CT) inhibit lymphocyte proliferation and decrease inflammatory cytokine production. We hypothesized that equine MSCs inhibit T cell proliferation through secreted mediators and that MSCs from different tissue sources decrease T cell proliferation through different mechanisms. To test our hypotheses, we inhibited interleukin-6 (IL-6), nitric oxide (NO), and prostaglandin E2 (PGE2) to determine their impact on stimulated T cell proliferation. We also determined how equine MSCs modulate lymphocyte proliferation either via cell cycle arrest or apoptosis. Inhibition of IL-6 or NO did not reverse the immunomodulatory effect of MSCs on activated T cells. In contrast, inhibition of PGE2 restored T cell proliferation, restored the secretion of tumor necrosis factor-α and interferon-γ, and increased IL-10 levels. MSCs from solid-tissue-derived sources, AT and CT, inhibited T cell proliferation through induction of lymphocyte apoptosis while blood-derived MSCs, BM and CB, induced lymphocyte cell cycle arrest. Equine MSCs from different tissue sources modulated immune cell function by both overlapping and unique mechanisms. MSC tissue source may determine immunomodulatory properties of MSCs and may have very practical implications for MSC selection in the application of MSC therapy.

AB - Mesenchymal stem cells (MSCs) are used in both human clinical trials and veterinary medicine for the treatment of inflammatory and immune-mediated diseases. MSCs modulate inflammation by decreasing the cells and products of the inflammatory response. Stimulated equine MSCs from bone marrow (BM), adipose tissue (AT), cord blood (CB), and umbilical cord tissue (CT) inhibit lymphocyte proliferation and decrease inflammatory cytokine production. We hypothesized that equine MSCs inhibit T cell proliferation through secreted mediators and that MSCs from different tissue sources decrease T cell proliferation through different mechanisms. To test our hypotheses, we inhibited interleukin-6 (IL-6), nitric oxide (NO), and prostaglandin E2 (PGE2) to determine their impact on stimulated T cell proliferation. We also determined how equine MSCs modulate lymphocyte proliferation either via cell cycle arrest or apoptosis. Inhibition of IL-6 or NO did not reverse the immunomodulatory effect of MSCs on activated T cells. In contrast, inhibition of PGE2 restored T cell proliferation, restored the secretion of tumor necrosis factor-α and interferon-γ, and increased IL-10 levels. MSCs from solid-tissue-derived sources, AT and CT, inhibited T cell proliferation through induction of lymphocyte apoptosis while blood-derived MSCs, BM and CB, induced lymphocyte cell cycle arrest. Equine MSCs from different tissue sources modulated immune cell function by both overlapping and unique mechanisms. MSC tissue source may determine immunomodulatory properties of MSCs and may have very practical implications for MSC selection in the application of MSC therapy.

UR - http://www.scopus.com/inward/record.url?scp=84901299559&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901299559&partnerID=8YFLogxK

U2 - 10.1089/scd.2013.0537

DO - 10.1089/scd.2013.0537

M3 - Article

C2 - 24438346

AN - SCOPUS:84901299559

VL - 23

SP - 1258

EP - 1265

JO - Stem Cells and Development

JF - Stem Cells and Development

SN - 1547-3287

IS - 11

ER -